What Families Should Expect From LDN: Side Effects, Timing, and Safety

By Natalie Hernandez, MD, Director of Metabolic Health & Inflammation, LIFE Pediatric Endocrinology and Toni Kim, MD, Founder, LIFE Pediatric Endocrinology

The short answer

Most side effects of low dose naltrexone (LDN) are mild, appear in the first one to two weeks, and fade on their own. The most common ones are vivid dreams, trouble falling asleep, headache, and mild stomach upset. In clinical trials, tolerability is close to placebo. The one true contraindication is opioid use, because naltrexone blocks opioid receptors and can trigger withdrawal. Almost everything else can be managed by changing the dose or the time of day it is taken.

Key takeaways

• LDN is naltrexone at roughly 1.5 to 4.5 mg per day, about one-tenth to one-thirtieth of the 50 mg dose used for addiction medicine. The side effect profile at that dose is very different.
• Vivid dreams and sleep disturbance are the most frequently reported effects. They usually resolve within one to three weeks, and moving the dose to the morning often solves them entirely.
• Long-term side effects have not been well characterized because most published trials run 8 to 16 weeks. This is a real limitation, and families deserve to hear it plainly.
• The FDA has not established safe use of naltrexone under age 18, and its label addresses only the 50 mg dose. All pediatric LDN is off-label.
• LDN is not habit-forming. Stopping it does not cause withdrawal. What people notice when they stop is the gradual return of the symptoms LDN was helping.
• Opioid pain medication is the one thing that must be avoided. This matters more for teenagers than parents expect, because wisdom teeth, sports injuries, and orthopedic surgery are common.
• In a child or teen with thyroid disease, LDN can shift how much thyroid hormone the body needs. Thyroid labs should be rechecked after starting.

What low dose naltrexone actually is

Naltrexone has been in use since the 1980s at 50 mg per day, where it works as a sustained opioid receptor blocker for alcohol and opioid use disorder. Low dose naltrexone is the same molecule at a fraction of that amount.

At 1.5 to 4.5 mg, naltrexone produces only a brief, partial blockade of opioid receptors. The body responds by increasing its own endorphin and enkephalin signaling. Separately, and probably more importantly for the families we care for, naltrexone at these doses acts on microglia through Toll-like receptor 4, which quiets neuroinflammation. Those two mechanisms are why LDN shows up in the literature for fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome rather than for addiction.

This distinction matters for side effects. Almost every side effect list a parent finds online is drawn from studies of 50 mg naltrexone. Those lists are not wrong, but they describe a different medication experience than the one their child will have.

Two other clarifications we make often in our clinic:

• LDN is not a weight-loss medication. Naltrexone combined with bupropion is used for weight management in some adults. LDN at 1.5 to 4.5 mg is a different use at a different dose, and we do not prescribe it as a weight intervention.
• LDN is prescribed off-label. No LDN indication is FDA-approved. That is not a reason to avoid it, but it is a reason to be honest about the evidence, which is what the rest of this article does.

The most common side effects of low dose naltrexone

The pattern that matters more than the list: side effects from LDN cluster at the beginning and at dose increases. A symptom that appears on day three of a new dose and is gone by day twelve is behaving the way LDN normally behaves. A symptom that appears at month four, out of nowhere, usually has a different explanation and deserves a real workup rather than an assumption that the medication caused it.

Why vivid dreams happen

LDN was traditionally dosed at bedtime, based on an older theory about overnight endorphin rebound. Because the medication's peak activity lands during sleep, dream intensity and sleep fragmentation are the effects patients notice first.

In our experience, this is the single most common reason a family calls in the first month, and it is also the easiest to fix. Morning dosing resolves it for most patients without any loss of benefit. Parents are often relieved to learn the fix is that simple.

How long do low dose naltrexone side effects last?

For most patients, one to two weeks. Sleep and dream effects tend to settle first. Headache and stomach upset usually resolve within the first seven to ten days.

Three things extend that window:

1. Titrating too fast. Going from 1.5 mg to 4.5 mg in a week restarts the adjustment period at each step. Slower is genuinely faster here.
2. Underlying mast cell activity or heightened medication sensitivity. Some patients react to almost any pharmacologic change. These children do better starting well below 1.5 mg using a compounded liquid, and increasing by small increments every two weeks.
3. A dose that is simply too high for that individual. Not everyone needs 4.5 mg. Some patients do best at 1.5 to 3 mg, and pushing past their ceiling produces side effects without added benefit.

If side effects have not settled after three to four weeks at a stable dose, that is information, not failure. It usually means the dose needs to come down.

Long-term side effects of low-dose naltrexone

Here is the honest state of the evidence: long-term side effects of LDN have not been well studied. Most published trials run 8 to 16 weeks. Retrospective series and clinical registries suggest that patients who tolerate LDN in the first month generally continue to tolerate it, but that is observational data, not a long-term safety trial.

What we do know:

• Concerns about liver injury with naltrexone come from studies using supratherapeutic doses above 300 mg per day, which is orders of magnitude above the 0.5 to 6 mg LDN range. Naltrexone remains contraindicated in acute hepatitis or liver failure.
• Naltrexone is cleared by the liver rather than the kidneys, so active liver disease is a reason for caution and monitoring.
• Where trial data has been pooled, LDN has not separated from placebo on adverse events. The Cochrane review of Crohn's trials found no statistically significant difference in withdrawals due to adverse events, and none in sleep disturbance, vivid dreams, headache, decreased appetite, nausea, or fatigue. No serious adverse events occurred in either study, though the reviewers graded the evidence low certainty because the numbers were small.
• Published LDN safety studies do not address high-risk pediatric subgroups. The favorable tolerability profile should be read as encouraging rather than settled.

What we do in practice: baseline labs before starting, a recheck at roughly three months, and periodic monitoring after that, with the interval set by the child's underlying condition rather than by the LDN itself. If a family is going to use a medication with a thin long-term dataset, the monitoring should be better than average, not worse.

Side effects of stopping low dose naltrexone

LDN is not habit-forming, and there is no withdrawal syndrome associated with stopping it. It can be discontinued without a taper.

What families actually notice when they stop is the gradual return of the symptoms LDN was managing, typically over one to four weeks. Pain, fatigue, brain fog, or GI symptoms drift back toward baseline. This is often how a family learns whether the medication was doing anything, and it is a reasonable reason to plan a short, deliberate trial off the medication once a child has been stable for a while.

Two exceptions worth naming:

• If sleep improved on LDN, sleep may loosen again after stopping. That is the underlying condition, not a rebound effect of the drug.
• If LDN was reducing autoimmune thyroid activity, thyroid hormone requirements may shift again after stopping. Thyroid labs should be rechecked.

What to avoid when taking low dose naltrexone

Opioid pain medication (the one that matters)

Naltrexone occupies opioid receptors. At the standard 50 mg dose, this precipitates withdrawal in a patient who is opioid-dependent. At LDN doses, precipitated withdrawal is rarely if ever seen clinically, and it remains largely a theoretical consideration. The practical issue for most families is different and more common: LDN can blunt or block the pain relief an opioid is supposed to provide.

For a teenager, that means:

• Tell the surgeon, oral surgeon, or ER physician that your child takes LDN. Wisdom teeth, ACL repairs, and fractures are the common scenarios.
• Hold LDN before planned surgery on the schedule your physician gives you, and restart it afterward once opioid pain control is finished.
• Check cough and cold medicines for codeine or hydrocodone, which still appear in some prescription cough syrups.
• If a child has been on ongoing opioid therapy, a washout period before starting LDN is standard practice, roughly 7 to 10 days for short-acting opioids and about 14 days for long-acting formulations, decided case by case by the prescribing physician.

Pregnancy and breastfeeding

Safety data in pregnancy and lactation is insufficient, and LDN is generally avoided. For adolescent patients, this belongs in the conversation at the time of prescribing, not as an afterthought.

Unsupervised dose escalation

More is not better with LDN. Above roughly 4.5 mg per day, naltrexone starts behaving more like its addiction-treatment dose, and the low-dose mechanisms that produce the benefit are lost. Doubling the dose to chase a better result is one of the more common self-directed mistakes we correct.

Poor-quality compounding

LDN is not commercially available at these strengths. It is compounded, and naltrexone is sensitive to moisture and temperature, which makes consistent low-strength dosing genuinely difficult. We work with compounding pharmacies we have vetted, and we specify liquid formulations when weight-based dosing or very small increments are needed.

Side effects of LDN in children and teenagers

This is where most articles on this topic go quiet, and it is the part our families need.

The pediatric evidence base is small but real. It is also worth stating plainly what it is not: the FDA has not established safe use of naltrexone in patients under 18. The drug label addresses only conventional 50 mg dosing. All pediatric LDN use is off-label and rests on limited evidence.

What that limited evidence shows:

• The strongest pediatric data come from a randomized, double-blind, placebo-controlled pilot trial in children ages 6 to 17 with moderate to severe Crohn's disease, dosed at 0.1 mg/kg per day (maximum 4.5 mg). Oral naltrexone was well tolerated with no serious adverse events, with safety tracked through physical exams and blood chemistries, alongside a meaningful drop in disease activity scores.
• A Cochrane review pooling the pediatric and adult Crohn's trials found no statistically significant difference versus placebo in withdrawals due to adverse events, or in sleep disturbance, vivid dreams, headache, decreased appetite, nausea, or fatigue. No serious adverse events occurred in either study. The reviewers graded the evidence as low certainty because the event counts were too small to draw firm conclusions.
• A 2021 review in the Journal of Pediatric Pharmacology and Therapeutics addressed developmental considerations for naltrexone in children and adolescents specifically.
• A retrospective analysis examined LDN in pediatric chronic pain.
• A 2026 multi-center review of 62 children and young adults (mean age 15.6) with long COVID prescribed LDN across three pediatric programs found that discontinuation was driven mostly by lack of benefit (about 44%) rather than by side effects (about 25%).

That last number is the one we quote to parents. When LDN does not work out in kids, it is usually because it did not help, not because it caused harm.

The honest caveat on all of it: these studies are small, and none of them looked at higher-risk pediatric subgroups. "Well tolerated in the children who have been studied" is not the same as "proven safe for every child," and we say so to families before we prescribe rather than after.

How pediatric dosing differs. Children are typically dosed by weight, often starting around 0.1 mg/kg and capping near 4.5 mg. Younger or smaller children, and children with heightened medication sensitivity, are usually started on a compounded liquid so the dose can be raised in small, controlled steps. A 60-pound nine-year-old and a 140-pound sixteen-year-old should not be started on the same capsule, and the fact that both are sometimes handed 4.5 mg is a real source of avoidable side effects.

The endocrine considerations most articles miss

Because LIFE is an endocrinology practice, we watch a set of interactions that general LDN articles rarely mention.

Thyroid disease

We prescribe LDN in some children and teenagers with Hashimoto's thyroiditis, and we are careful about how we describe what it is doing.

What LDN is not: it is not a replacement for thyroid hormone. A thyroid gland that cannot make enough hormone still needs levothyroxine, and no dose of LDN changes that. Claims that LDN reliably lowers TPO or thyroglobulin antibodies, restores thyroid function, or reduces the need for thyroid medication are not established in controlled trials. One large analysis of nearly 900 patients with hypothyroidism found no reduction in thyroid hormone prescriptions after starting LDN.

What we are actually targeting is the symptom burden that thyroid replacement alone often does not fix: fatigue, aching, brain fog, and poor sleep in a child whose labs look adequate. That is an inflammation problem more than a hormone problem, and it is where LDN has a plausible role.

Because we cannot rule out a shift in thyroid hormone requirements in an individual patient, we recheck thyroid function within 6 to 12 weeks of starting LDN and after any meaningful dose change. If new anxiety, palpitations, heat intolerance, or trouble sleeping appear, we check labs before assuming it is an LDN side effect, because over-replacement looks nearly identical.

Insulin resistance and metabolic health

Inflammation and insulin resistance travel together. When we use LDN as part of an inflammation strategy in a teenager who also has insulin resistance or PMOS, we are tracking metabolic markers alongside symptom response, because improvements and side effects can both come from more than one direction at once.

Autonomic symptoms

In patients with POTS and mast cell activation, early LDN side effects can be hard to separate from the condition itself. Fatigue, headache, and sleep disruption are already part of the picture. This is precisely why we titrate slowly and change one variable at a time. A family that starts LDN, a new supplement, and a new sleep schedule in the same week has made the next month uninterpretable.

What we use LDN for at LIFE Pediatric Endocrinology

Families often find this article while trying to decide whether LDN is worth trying at all. Here is where it fits in our practice, and how strong the evidence is behind each use.

Autoimmune thyroid disease (Hashimoto's). Used as an add-on for the fatigue, aching, and brain fog that persist after thyroid hormone is optimized. Never as a substitute for levothyroxine. Evidence: mechanistic and clinical experience, not controlled trials.

POTS and dysautonomia. Used for fatigue, pain, post-exertional worsening, and sleep. The proposed mechanism is reduced neuroinflammation through microglial signaling, and there is laboratory work on naltrexone restoring TRPM3 ion channel function in natural killer cells in related conditions. Evidence: small observational studies and clinical experience.

Mast cell activation. Used for the inflammatory and pain components. These patients are the most medication-sensitive group we treat, and they need the slowest titration and often the lowest final dose. Evidence: mechanistic and clinical experience.

Post-viral syndromes, including long COVID. The most developed pediatric dataset. A 2026 review across three pediatric long COVID programs described real-world prescribing in 62 children and young adults, and a federally funded pediatric trial is now underway. Evidence: observational, with controlled data coming.

Chronic pain and inflammatory conditions. The best-evidenced adult use, particularly fibromyalgia, where a systematic review found reduced pain and improved quality of life across the available trials. A pediatric chronic pain analysis has also been published.

A consistent theme: LDN is an adjunct. In every one of these conditions, we are also addressing sleep, nutrition, activity pacing, salt and fluid status where relevant, and the underlying endocrine or metabolic driver. When LDN works, it works alongside those things. We have not seen it work instead of them.

We also tell families what would make us stop. If a child has been at a stable therapeutic dose for three to four months with no meaningful change, we take LDN off the plan rather than let it accumulate on the medication list.

When a side effect means the dose is wrong versus when LDN is wrong

A useful distinction for families:

The dose is probably wrong if:

• The symptom started within days of beginning or increasing the dose
• It is sleep, dreams, headache, or mild GI upset
• It improved once before, at a lower dose

LDN may be the wrong medication if:

• There is a rash, hives, swelling, or difficulty breathing (stop and call immediately)
• Side effects persist at the lowest tolerable dose after several weeks
• There has been no benefit after three to four months at a stable therapeutic dose

That last point deserves emphasis. If a child has been at a full dose for three to four months with no meaningful change in symptoms, LDN is unlikely to become the answer with more time. Continuing a medication that is not working is its own kind of harm, and we would rather reassess than let a prescription drift.

When to call your physician

Call the same day for:

• Rash, hives, facial or throat swelling, or difficulty breathing
• Yellowing of the eyes or skin, dark urine, or persistent right-sided abdominal pain
• Any planned surgery or procedure where opioid pain medication may be used
• New agitation, confusion, or a significant mood change

Call within a few days for:

• Side effects that have not settled after three weeks at a stable dose
• Sleep disruption that is affecting school performance
• New palpitations, heat intolerance, or anxiety in a child with thyroid disease

How we approach LDN at LIFE Pediatric Endocrinology

We use LDN as one part of a plan, never as the whole plan.

Before we prescribe it, we do the work of understanding why a child is inflamed. That means a thorough history where the family is allowed to finish their story, comprehensive testing across metabolic, endocrine, inflammatory, and nutritional markers, and an honest conversation about what the medication can and cannot do. Nutrition, sleep, movement, and stress physiology are handled inside the medical visit rather than delegated to a handout, because in this population they change outcomes as much as any prescription does.

When we do prescribe LDN, we start low, move slowly, change one thing at a time, and check in during the titration rather than at a visit three months later. Families reach their physician directly. That access is the reason side effects in our practice usually get solved with a phone call instead of a discontinued prescription.

LIFE Pediatric Endocrinology is a national concierge pediatric endocrinology practice. We see patients by telemedicine across the country and in person at our offices in Austin, Sandy Springs, Beverly Hills, Newport Beach, and Brentwood, with our physicians traveling to additional cities by arrangement.

Frequently asked questions

What are the side effects of low dose naltrexone? The most common side effects of low dose naltrexone are vivid dreams, difficulty sleeping, headache, and mild nausea or stomach upset. Less commonly, patients report fatigue, anxiety, or irritability. In clinical trials, overall tolerability is close to placebo, and most effects appear in the first one to two weeks and resolve on their own.

How long do low dose naltrexone side effects last? Most last one to two weeks. Sleep and dream effects usually settle first. Side effects that persist beyond three to four weeks at a stable dose typically mean the dose is too high or was increased too quickly, and lowering it usually resolves them.

What are the long-term side effects of low-dose naltrexone? Long-term side effects have not been well characterized, because most published trials last only 8 to 16 weeks. No consistent pattern of long-term harm has emerged from the available data, but the absence of long-term studies is a genuine limitation. Periodic monitoring, including liver function, is reasonable for anyone on LDN for an extended period.

Are there side effects of stopping low dose naltrexone? LDN is not habit-forming and does not cause withdrawal, so it can be stopped without a taper. What most people notice is the gradual return of the symptoms LDN was managing, usually over one to four weeks. In patients with autoimmune thyroid disease, thyroid hormone requirements may shift again after stopping and labs should be rechecked.

What should you avoid when taking low dose naltrexone? Avoid opioid pain medication, including codeine-containing cough syrups, because naltrexone blocks opioid receptors and can block pain relief or trigger withdrawal. Tell any surgeon or emergency physician that you take LDN. LDN is also generally avoided in pregnancy and breastfeeding, and doses should not be increased without physician guidance.

Is low dose naltrexone safe for children and teenagers? Published pediatric data is limited but reassuring. In a randomized, placebo-controlled pilot trial in children ages 6 to 17 with Crohn's disease, LDN was well tolerated with no serious adverse events, and a Cochrane review pooling the pediatric and adult Crohn's trials found no statistically significant difference from placebo in adverse events or withdrawals. The FDA has not established safe use of naltrexone under age 18, so all pediatric LDN is off-label. Dosing should be weight-based, started low, and supervised by a physician experienced with it.

Does low dose naltrexone cause weight gain or weight loss? LDN at 1.5 to 4.5 mg is not a weight-loss medication and is not prescribed for that purpose in our practice. Naltrexone combined with bupropion is used for weight management in some adults, but that is a different medication at a much higher dose.

Can low dose naltrexone be used for hypothyroidism or Hashimoto's? LDN is used by some physicians, including ours, as an add-on for the fatigue, aching, and brain fog that persist in Hashimoto's after thyroid hormone is optimized. It does not replace thyroid hormone, and controlled evidence has not shown that it lowers thyroid antibodies or reduces levothyroxine requirements. One analysis of nearly 900 patients with hypothyroidism found no reduction in thyroid hormone prescriptions after starting LDN.

Can low dose naltrexone affect thyroid medication? It may in an individual patient, so thyroid function should be rechecked within 6 to 12 weeks of starting LDN and after dose changes. This matters because symptoms of thyroid over-replacement, including anxiety, palpitations, and trouble sleeping, look almost identical to early LDN side effects. Checking labs tells you which one you are dealing with.

Is low dose naltrexone used for POTS and MCAS? Yes, as one part of a broader plan. In POTS and mast cell activation, LDN is used for fatigue, pain, and post-exertional symptoms, with reduced neuroinflammation as the proposed mechanism. The evidence is observational rather than from randomized trials. Patients with mast cell activation are typically the most medication-sensitive and need slower titration and lower doses.

Why does low dose naltrexone cause vivid dreams, and can they be avoided? LDN is traditionally taken at bedtime, so its peak activity overlaps with sleep, which intensifies dreaming for some patients. Moving the dose to the morning resolves this for most people without reducing the benefit.

Talk with a pediatric endocrinologist about your child

If your child is dealing with inflammation, fatigue, pain, autonomic symptoms, or a metabolic condition and you are trying to decide whether LDN belongs in the plan, we would be glad to look at the whole picture with you.

Request a consultation with Dr. Natalie Hernandez →

About the authors

Natalie Hernandez, MD is Director of Metabolic Health & Inflammation at LIFE Pediatric Endocrinology. She completed her pediatric endocrinology fellowship and pediatrics residency at Duke University Hospital and earned her MD from Sidney Kimmel Medical College at Thomas Jefferson University. Her research at Duke focused on metabolomics and insulin resistance in youth-onset type 2 diabetes, with work published in the Journal of Clinical Endocrinology & Metabolism and presented nationally at the Pediatric Endocrine Society and ENDO, where she received an Outstanding Abstract Award and a Presidential Poster Award. She is board certified in Pediatrics. Dr. Hernandez cares for children and teenagers with insulin resistance, obesity, PMOS, POTS, mast cell activation, and inflammatory conditions, and she practices in English and Spanish. She sees patients in Houston, Austin, Dallas, Atlanta, Nashville, Miami, Los Angeles, Newport Beach, and Atherton, and by telemedicine.

Toni Kim, MD is the Founder of LIFE Pediatric Endocrinology and a board-certified pediatric endocrinologist with more than 20 years of experience. She built LIFE around longer visits, direct physician access, and an integrative approach that treats nutrition and lifestyle as part of medical care rather than an afterthought.

Medical disclaimer

This article is for general education and does not constitute medical advice, diagnosis, or treatment. Low dose naltrexone is prescribed off-label, and no LDN indication is FDA-approved. Do not start, stop, or change any medication based on this article. Talk with your child's physician about your child's specific situation. If your child is having a medical emergency, call 911.

Sources

1. Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol. 2013. https://pubmed.ncbi.nlm.nih.gov/23188075/
2. Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010410.pub3/full
3. Naltrexone Hydrochloride, FDA Drug Label. U.S. Food and Drug Administration. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adb7c4dc-221a-4d91-9687-0d78913a92ad
4. Gouda AHK, Aitcheson NEC, Steadman KJ. Low-dose naltrexone: what is the evidence? A narrative review. Advances in Therapy. 2026. https://doi.org/10.1007/s12325-026-03612-5
5. Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systematic review. Curr Pain Headache Rep. 2020. https://doi.org/10.1007/s11916-020-00898-0
6. Poliwoda S, Noss B, Truong GTD, et al. The utilization of low dose naltrexone for chronic pain. CNS Drugs. 2023. https://doi.org/10.1007/s40263-023-01018-3
7. Stancil SL, et al. Developmental considerations for the use of naltrexone in children and adolescents. J Pediatr Pharmacol Ther. 2021;26(7):675-695.
8. Theriault C, Oyelola O, Zempsky WT. The efficacy of low-dose naltrexone in pediatric chronic pain: a retrospective analysis. The Journal of Pain. 2023.
9. Villatoro C, Yonts AB, Barter T, Mohandas S, Malone LA. Low dose naltrexone prescribing practices for children and adolescents with long COVID. medRxiv, 2026. https://www.medrxiv.org/content/10.64898/2026.02.20.26346719v1
10. Toljan K, Vrooman B. Low-dose naltrexone (LDN): review of therapeutic utilization. Medical Sciences. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313374/
11. Partridge S, Quadt L, Bolton M, et al. A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. Heliyon, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189400/
12. O'Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250701/
13. Sasso EM, Muraki K, Eaton-Fitch N, et al. Low dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients. Frontiers in Molecular Biosciences, 2025.